74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Protagonist Therapeutics Inc
Closed
SectorHealthcare
48.15 2.86
Overview
Share price change
24h
Min
46.31
Max
48.89
Income | 165M 132M |
|---|---|
Sales | 166M 171M |
P/E Sector Avg | 11.433 63.778 |
EPS | 1.98 |
Profit margin | 77.166 |
Employees | 126 |
EBITDA | 168M 127M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +44.62% upside |
Next Earnings | 5 May 2025 |
|---|
Market Cap | 791M 3B |
|---|---|
Previous open | 45.29 |
Previous close | 48.15 |
News Sentiment
By Acuity
20%
80%
41 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Protagonist Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Protagonist Therapeutics Inc Forecast
Price Target
By TipRanks
44.62% upside
12 Months Forecast
Average 67.8 USD 44.62%
High 82 USD
Low 38 USD
Based on 10 Wall Street analysts offering 12 month price targets forProtagonist Therapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
41 / 386 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Protagonist Therapeutics Inc
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
